SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
NervGen Pharma Corp. (NGENF) , forward earnings yield 0.25%. PEG 0.02 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 395.0
- PEG Ratio 0.02 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Overall SharesGrow Score: 26/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
75/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NGENF
Valuation Multiples
P/E (TTM)0.0
Forward P/E395.0
PEG Ratio0.02
Forward PEG0.02
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.36
Forward EPS (Est.)$0.01
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield0.25%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$0.00 |
$0.00 |
$-11.81K |
- |
| 2018 |
$-0.05 |
$0.00 |
$-1.36M |
- |
| 2019 |
$-0.38 |
$0.00 |
$-9.77M |
- |
| 2020 |
$-0.35 |
$0.00 |
$-11.19M |
- |
| 2021 |
$-0.32 |
$0.00 |
$-12.73M |
- |
| 2022 |
$-0.39 |
$0.00 |
$-20.72M |
- |
| 2023 |
$-0.38 |
$0.00 |
$-22.38M |
- |
| 2024 |
$-0.36 |
$0.00 |
$-24.01M |
- |
